Compare Macy's Inc (M) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Macy's Inc vs Sana Biotechnology Inc — how do they compare? Macy's Inc trades at $23.75 (market cap $6.45B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Macy's Inc is far larger — about 5.7× Sana Biotechnology Inc's market cap, and Macy's Inc pays a 3.12% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| M | SANA | |
|---|---|---|
Market Cap | $6.45B | $1.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $26.21 | $5.92 |
52-Week Low | $12.73 | $2.68 |
Enterprise Value | $10.26B | $1.05B |
Dividend Yield | 3.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Macy's stock trades at $23.78, down 4.5% over 24 hours, with technical indicators showing a bullish moving average signal but neutral oscillators. The company demonstrates improving fundamentals with three consecutive quarterly earnings beats and positive cash flow trends. Recent institutional buying and analyst coverage reflect cautious optimism amid the company's turnaround efforts.
The stock presents value investment potential with attractive valuation multiples (P/E 10.13, P/S 0.3) and improving profitability. Key risks include retail sector headwinds and execution of the 'Bold New Chapter' strategy. The consensus price target of $24.83 suggests modest upside potential from current levels.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
